Literature DB >> 10597891

Transfer of morphine across the human placenta and its interaction with naloxone.

E A Kopecky1, C Simone, B Knie, G Koren.   

Abstract

The purpose of this investigation was to measure the transfer rate and clearance of morphine across the placenta with and without naloxone. Term human placental cotyledons were perfused in vitro. The placenta was perfused with 50 ng/mL of morphine in the absence (n=4) and presence (n=5) of 100 ng/mL of naloxone. Maternal and fetal samples were collected. Student's t-test or one-way repeated measures ANOVA were used for all comparisons. The maternal-to-fetal morphine transfer rate was 0.73+/-0.44 ng/mL/min in the morphine and 0.69+/-0.26 ng/mL/min in the morphine-naloxone experiments (p=0.89). The clearance of morphine was 0.89+/-0.39 mL/min without naloxone and 0.87+/-0.27 mL/min with naloxone (p=0.92). Final morphine concentrations in the morphine experiments were 9.78+/-6.17 ng/mL (maternal) and 3.43+/-2.14 ng/mL (fetal) and 10.04+/-3.89 ng/mL (maternal) and 4.16+/-1.64 ng/mL (fetal) in the morphine-naloxone experiments. Morphine readily crosses the term human placenta. Naloxone does not alter placental transfer or clearance of morphine, suggesting that transfer across the placental barrier is not altered by changes in vascular resistance. Placental retention of morphine prolongs fetal exposure to morphine.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10597891     DOI: 10.1016/s0024-3205(99)00503-2

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  9 in total

1.  Application of Model Informed Precision Dosing to Address the Impact of Pregnancy Stage and CYP2D6 Phenotype on Foetal Morphine Exposure.

Authors:  Sarah Badaoui; Ashley M Hopkins; A David Rodrigues; John O Miners; Michael J Sorich; Andrew Rowland
Journal:  AAPS J       Date:  2021-01-06       Impact factor: 4.009

2.  Maternal oral consumption of morphine increases Bax/Bcl-2 ratio and caspase 3 activity during early neural system development in rat embryos.

Authors:  Shiva Nasiraei-Moghadam; Behrang Kazeminezhad; Leila Dargahi; Abolhassan Ahmadiani
Journal:  J Mol Neurosci       Date:  2009-11-21       Impact factor: 3.444

3.  The effect of morphine consumption on plasma corticosteron concentration and placenta development in pregnant rats.

Authors:  Masoomeh Kazemi; Hedayat Sahraei; Mahnaz Azarnia; Leila Dehghani; Hossein Bahadoran; Elaheh Tekieh
Journal:  Iran J Reprod Med       Date:  2011

4.  Evaluating the effects of oral morphine on embryonic development of cerebellum in wistar rats.

Authors:  Narges A Niknam; Mahnaz Azarnia; Hossein Bahadoran; Masoomeh Kazemi; Elaheh Tekieh; Mina Ranjbaran; Hedayat Sahraei
Journal:  Basic Clin Neurosci       Date:  2013

5.  Opioid use disorder in pregnancy.

Authors:  Kristin Harter
Journal:  Ment Health Clin       Date:  2019-11-27

6.  Maternal Methadone Destabilizes Neonatal Breathing and Desensitizes Neonates to Opioid-Induced Respiratory Frequency Depression.

Authors:  Austin D Hocker; Nina R Morrison; Matthew L Selby; Adrianne G Huxtable
Journal:  Front Physiol       Date:  2021-02-25       Impact factor: 4.566

7.  In Silico Modeling for Ex Vivo Placental Transfer of Morphine.

Authors:  Harvey Ho; Shengjie Zhang; Ken Kurosawa; Koji Chiba
Journal:  J Clin Pharmacol       Date:  2022-09       Impact factor: 2.860

8.  The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.

Authors:  W O Farid; S A Dunlop; R J Tait; G K Hulse
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

9.  Identification of site of morphine action in pregnant wistar rat placenta tissue: a c(14)-morphine study.

Authors:  Masoomeh Kazemi; Hedayat Sahraei; Leila Dehghani
Journal:  Cell J       Date:  2012-08-31       Impact factor: 2.479

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.